Sippican Capital Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Sippican Capital Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,684	Closed	-$165K	–	120
2023 Q3	$165K	Sell	10,684 -70,115	-87%	-$1.09M	0.15%	105
2023 Q2	$1.27M	Sell	80,799 -1,436	-2%	-$23.5K	1.17%	37
2023 Q1	$1.36M	Hold	82,235	–	–	1.3%	30
2022 Q4	$1.28M	Sell	82,235 -5,225	-6%	-$73K	1.23%	35
2022 Q3	$1.13M	Buy	87,460 +1,415	+2%	+$19.7K	1.18%	36
2022 Q2	$1.21M	Buy	86,045 +5,555	+7%	+$79.3K	1.2%	36
2022 Q1	$1.15M	Buy	80,490 +10,940	+16%	+$161K	0.96%	44
2021 Q4	$948K	Buy	69,550 +26,230	+61%	+$368K	0.81%	51
2021 Q3	$710K	Buy	43,320 +33,110	+324%	+$556K	0.62%	63
2021 Q2	$172K	Buy	+10,210	New	+$174K	0.15%	111

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Sippican Capital Advisors's TAK Position: Q4 2023 in Review

Sippican Capital Advisors sold out of Takeda Pharmaceutical (TAK) in Q4 2023, closing a stake of 10,684 shares — an estimated $165K sold.

Sippican Capital Advisors first reported a position in TAK in Q2 2021 and held it in 10 quarters. The position peaked at $1.36M in Q1 2023. 306 funds tracked by Wall St. Rank hold TAK as of Q4 2023.

Sippican Capital Advisors reported no remaining Takeda Pharmaceutical position as of Q4 2023 after selling out during the quarter.
Sippican Capital Advisors sold 10,684 Takeda Pharmaceutical shares in Q4 2023, an estimated $165K.
Sippican Capital Advisors first reported a position in Takeda Pharmaceutical in Q2 2021 and held it in 10 quarters.
Sippican Capital Advisors's Takeda Pharmaceutical position peaked at $1.36M in Q1 2023.
306 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2023.

Based on Sippican Capital Advisors's 13F filing for Q4 2023, filed 30 Jan 2024.